Amanta Healthcar Q1 FY27 Earnings Call — Analysis (NSE: AMANTA)
SteriPort Line 3 expansion delayed by one quarter, now commissioning late-August 2026, with management guiding FY28 revenue of ~₹425 Cr and EBITDA margin of 25–26%.
The take
Q1FY27 Revenue ₹69 Cr ( +5% YoY ) . New guidance — FY28 steriport line 3 peak revenue ₹120 Cr . New story: SteriPort expansion delayed but imminent .
Results
Revenue ₹69 Cr +5% YoY; EBITDA ~₹15 Cr with margin ~22%, absorbing overheads for delayed SteriPort expansion and short-term polymer cost spike.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹69 Cr | +5% | yoy · Q1FY27 |
| EBITDA | ₹15 Cr | none · Q1FY27 | |
| EBITDA margin | 22% | point_in_time · Q1FY27 | |
| SteriPort Line 3 peak revenue (annualized) | ₹120 Cr | none · peak annualized · as stated by management | |
| FY27 estimated revenue (ex-SVP) | ₹370 Cr | none · FY27 · management guidance | |
| FY28 estimated revenue | ₹425 Cr | none · FY28 · management guidance | |
| FY28 estimated EBITDA margin | 25–26% | none · FY28 · management guidance | |
| SteriPort Line 3 total capex | ₹90 Cr | point_in_time · project · ₹80 Cr spent so far | |
| SVP facility total capex | ₹30 Cr | point_in_time · project · ₹7 Cr spent so far |
Guidance
Management guided FY27 revenue of ~₹370 Cr (ex-SVP) and FY28 revenue ~₹425 Cr with 25–26% EBITDA margin, SteriPort Line 3 commissioning by end-August 2026.
What management committed to
- [SteriPort Line 3] commercial production will begin in the last week of August 2026, subject to FDA inspection on 21 August 2026. — Q2FY27
- [SteriPort Line 3] will generate peak annualized revenue of ₹120 Cr. — ₹120 Cr, FY28
- FY27 revenue (excluding SVP) will be approximately ₹370 Cr. — ₹370 Cr, FY27
- FY28 consolidated revenue will be approximately ₹425 Cr. — ₹425 Cr, FY28
- FY28 consolidated EBITDA margin will be 25–26%. — 25–26%, FY28
- SteriPort Line 3 will contribute roughly ₹70 Cr to FY27 top line from September 2026 to March 2027. — ₹70 Cr, FY27
- SteriPort and SVP expansion will strengthen revenue mix towards higher-margin products and maintain current profitability. — coming quarters
- [SVP facility] will commence commercial operations during Q4 FY27. — Q4FY27
- First inhalation product from SVP pipeline will be commercialized by 15 September 2026. — Q2FY27
- 20 SVP products in the pipeline will be completed within 18 months from August 2026. — 20 products, FY28
- 10.8 MW captive solar power project will save approximately ₹9 Cr annually (₹75 lakh per month). — ₹9 Cr, FY27
- Consolidated EBITDA margin will expand by 4–5 percentage points (including solar captive benefit) compared to FY26 level of ~21%. — 4–5% expansion, FY28
Key themes
Capacity expansion, export pipeline, and cost levers
How the narrative shifted
- SteriPort expansion delayed but imminent: Management positions the four-month civil delay as absorbed and the late-August commissioning as a near-term catalyst that will unlock a ₹120 Cr annualized revenue stream.
- Export-centric SVP pipeline as next growth engine: SVP facility on track for Q4 FY27; 20 inhalation/ophthalmic products under development for advanced markets, with first commercialization mid-September 2026, set to drive FY28+ growth and margin uplift.
- Operating leverage and cost optimization: Overhead pre-absorption during delay will flip to operating leverage; solar plant commissioned June 2026 adds ₹9 Cr annual savings; together drive 4–5pp margin expansion target.
- Input cost volatility absorbed via pricing: Polymer prices spiked 70–80% for 2 months due to Middle East crisis; management took ₹1.50 price increase vs ₹2.25 cost impact, expecting to absorb the spike over 1–2 quarters with polymer prices now normalizing.
- Disciplined capital allocation to sterile niche: Management explicitly ruled out unrelated diversification; long-term vision confined to sterile dosage forms, with potential move to glass packaging and other delivery mechanisms only as a natural extension.
- Advanced regulated market re-entry with existing relationships: Management highlighted historical exports to Australia/Canada (only Indian company to export BFS injectables to those markets) and plans to re-enter with new capacity, targeting 60–70% of SVP revenue from advanced markets.
- Working capital structurally higher but debt declining: NWC days at 141, attributed to 15–25 day quarantine requirement typical for sterile injectables; debt reducing ₹30–35 Cr annually despite solar capex addition.
Operational commentary
- SteriPort Line 3 FDA plan approved; validation/qualification ongoing, commercial production targeted last week of August 2026 (subject to FDA inspection on 21 Aug). Line dedicated to 500 ml platform, improving output and overhead absorption.
- 10.8 MW captive solar power plant commissioned June 2026; expected to reduce power cost by ~₹9 Cr annually (~₹75 lakh/month savings).
- SVP expansion on track for commercial operations by Q4 FY27 (Feb–Mar 2027); FAT scheduled in USA second week of November 2026.
- SVP product pipeline: 20 products under development with 5 dedicated F&D scientists; first inhalation product commercialization targeted mid-September 2026.
- SteriPort capacity expansion from 6.6 Cr bottles/year to ~12 Cr bottles/year to serve oncology, critical care, anesthesiology, pediatrics demand.
- SVP revenue contribution ~20% of FY26; ~90% SVP revenue from exports, >60% of that from advanced/semi-advanced markets (UK, Ireland, Australia, Canada).
- Competitive landscape for special-feature plastic containers: Otsuka, Fresenius Kabi, B. Braun (city-focused), Aculife (limited national presence).
- New R&D and regulatory affairs team being built: target ~8–10 F&D and ~3–4 regulatory personnel; separate formulation development centre under construction.
Analyst Q&A
Q. Will Line 3 peak revenue of ₹110–120 Cr be realized within 12 months of commissioning?
That is an annualized number. On annualized basis we should be getting ₹120 Cr top line. Yes, within 12 months from commissioning.
Q. Does the 3–4% margin expansion include the ₹9 Cr solar savings?
We were targeting 5% expansion with ₹9 Cr saving, so 4–5% including solar captive benefit.
Q. What are the competitors in India for SteriPort?
Otsuka, Fresenius Kabi, B. Braun (confined to major cities), and Aculife (not nationwide).
Q. What are the next major growth drivers beyond SteriPort and SVP expansion?
Inhalation products, preservative-free ophthalmics, and diluents in advanced markets. Exploring other dosage forms beyond plastic packaging; clarity expected by December/January.
Q. Incremental ROCE on SteriPort Line 3 and SVP project?
SteriPort Line 3 ~16–17%, SVP ~14–15%. We are a little better than industry.
Research and educational content only. Not investment advice.